FDA Provides Update on Recall of Certain Philips Respironics Breathing Assistance Machines

Today, the U.S. Food and Drug Administration is providing an update related to the June 14, 2021, recall of certain Philips Respironics ventilators, continuous positive airway pressure (CPAP) and bilevel positive airway pressure (BiPAP) machines.

“Ensuring patients and providers have the most up-to-date information regarding the recall of these critical devices is a top priority for the FDA,” said Jeff Shuren, M.D., J.D., director of the FDA’s Center for Devices and Radiological Health. “We recognize that patients rely on these devices, and we are closely monitoring the company’s actions to ensure that the issues are resolved in a timely manner given the impact on patients. We are committed to continuing to regularly update the public about the status of this recall, including any new recommendations or actions regarding Philips Respironics’ devices.”

Before this time, Philips Respironics initiated a recall of certain ventilators, CPAP and BiPAP machines due to implicit health pitfalls related to polyester- grounded polyurethane sound abatement froth used in the bias. This particular froth may break down and can affect in serious injury, which can be life- hanging, beget endless impairment and bear medical intervention to help endless injury to druggies.

In response to the recall, the FDA lately conducted an examination of a Philips Respironics’ manufacturing installation to determine what may have caused or contributed to the froth issues and assess adherence to the agency’s conditions for quality manufacturing. FDA examinations are designed to include the review and evaluation of records, staff training, installation operations, medical device product and testing, and the systems in place to insure product quality. During the examination, the FDA investigator made several compliances that are outlined in an examination bonus report, also known as an “ FDA Form 483.” The FDA investigator handed a list of their compliances to the company. An FDA investigator’s list of examination compliances doesn’t constitute a final FDA determination of whether any condition is in violation of the Federal Food, Drug, and Cosmetic Act or any of its enforcing regulations. The FDA will review the company’s response and the summation of information available to the agency in determining applicable coming way.

Following the original recall, Philips Respironics developed a plan to repair the polyester- grounded polyurethane froth in the recalled CPAP and BiPAP bias with a different, silicone- grounded froth. The FDA originally approved this plan grounded, in part, on testing the company handed to the FDA in June on the new froth.

Still, during the manufacturing installation examination, the FDA attained fresh information, not preliminarily available to the agency, regarding the silicone- grounded froth used in a singular, analogous device retailed outside theU.S., which failed one safety test for the release of certain chemicals of concern, called unpredictable organic composites (VOCs). Analogous testing handed by Philips Respironics to the FDA on bias authorized for marketing in theU.S. had demonstrated respectable results. The FDA has requested that Philips Respironics retain an independent laboratory to perform fresh testing to determine what, if any, implicit safety pitfalls may be posed to cases by the silicone- grounded froth.

The FDA is apprehensive that cases have formerly entered bias with silicone- grounded froth as part of the form and replace program. At this time, the agency doesn’t have sufficient information to conclude whether the silicone- grounded froth being used in the repaired bias poses any threat to cases in theU.S.

Presently, while this independent testing is performed, the FDA doesn’t recommend that cases who have shared in the form and replace program discontinue use of their product. The FDA has reached this determination grounded on an overall benefit- threat assessment. At this time, the agency has determined that discontinuing use of one of these bias may be more dangerous to a case’s health and quality of life. The results from the independent testing are demanded to determine if the silicone- grounded froth used in the repaired bias does in fact present any pitfalls to cases, and the FDA will communicate those results to the public as soon as they’re available. Cases who have fresh enterprises should talk to their health care provider about the plan for their care and treatment.

As preliminarily communicated, the FDA recommends that cases presently using a recalled device that has not yet been repaired and replaced consult with their health care provider if they’ve fresh questions or enterprises to further determine whether cases should continue using the device, switch to another product or stop use.

The agency recognizes that numerous cases will have questions about what this information means for the status of their bias. The FDA has worked with cases and health care professional associations, including the American Sleep Apnea Association, the COPD ( habitual obstructive pulmonary complaint) Foundation, the Muscular Dystrophy Association, the Mended Hearts,Inc. and the American Academy of Sleep Medicine, and has included this feedback in the streamlined “ Constantly Asked Questions” to give helpful information to the public.
Affiliated Information
Philips Respironics FDA Form 483
Certain Philips Respironics Ventilators, BiPAP, and CPAP Machines Recalled Due to Implicit Health Pitfalls FDA Safety Communication
. Philips Respironics CPAP, BiPAP, and Ventilator Recall Constantly Asked Questions
The FDA, an agency within theU.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of mortal and veterinary medicines, vaccines and other natural products for mortal use, and medical bias. The agency also is responsible for the safety and security of our nation’s food force, cosmetics, salutary supplements, products that give off electronic radiation, and for regulating tobacco products.

Source link: https://www.fda.gov/